Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Liana Silveira Adriano

Liana Silveira Adriano

Federal University of Ceara, Brazil

Title: Hematologic complications after kidney transplantation: relationship to use of immunosuppressive

Biography

Biography: Liana Silveira Adriano

Abstract

Kidney transplantation is the best treatment for patients with chronic renal failure. Procedure that brings many benefits, but the later use of immunosuppressants is associated with the occurrence of adverse drug reactions. Immunosuppressive therapy tends to be specific in each transplant center and consist of a combination of various agents, including corticosteroids, calcineurin inhibitors, antimetabolites and mTOR inhibitors. Patients transplanted due to immunosuppression, have higher incidence of viral, bacterial and fungal infections such as cytomegalovirus, pneumocystosis and candidiasis, it is necessary to include prophylaxis antimicrobial therapy. Immunosuppressive drugs and prophylactic antibiotics are discussed in recent studies about the risk of haematological disorders and bone marrow, report pancytopenia, isolated manifestations of anemia, leucopenia and thrombocytopenia. More specific hematological disorders such as lymphocytic syndrome, erythrocytosis, thrombotic microangiopathy, lymphoproliferative disorder and hemophagocytic syndrome, are less frequent, but have been described. Hematologic changes in renal transplant patients can cause complications life-threatening, so they should be carefully monitored and treated by the health team. The aim of this study was to report the main after renal transplantation hematologic complications described in the literature and its association with the use of immunosuppressive as well as the strategies and protocols for the clinical management of these changes.